[EN] 1-{2-[(DIPHENYL)AMINO]-ETHYL}-PIPERIDINE-4-CARBOXYLIC ACID BENZYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CCR5 AGONISTS FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISEASES [FR] DÉRIVÉS DE BENZYLAMIDE DE L'ACIDE 1-{2-[(DIPHÉNYL)AMINO]-ÉTHYL}-PIPÉRIDINE-4-CARBOXYLIQUE ET COMPOSÉS ASSOCIÉS COMME AGONISTES DE CCR5 POUR LE TRAITEMENT DE MALADIES IMMUNES ET INFLAMMATOIRES
[EN] 1-{2-[(DIPHENYL)AMINO]-ETHYL}-PIPERIDINE-4-CARBOXYLIC ACID BENZYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CCR5 AGONISTS FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISEASES [FR] DÉRIVÉS DE BENZYLAMIDE DE L'ACIDE 1-{2-[(DIPHÉNYL)AMINO]-ÉTHYL}-PIPÉRIDINE-4-CARBOXYLIQUE ET COMPOSÉS ASSOCIÉS COMME AGONISTES DE CCR5 POUR LE TRAITEMENT DE MALADIES IMMUNES ET INFLAMMATOIRES
Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization. (C) 2013 Elsevier Masson SAS. All rights reserved.